HLA class I antigen loss, tumor immune escape and immune selection
HLA class I antigen loss, tumor immune escape and immune selection
复制标题
DOI：
10.1016/s0264-410x(02)00386-9
复制
发表时间：
2002-12-19
期刊：
影响因子：
5.5
通讯作者：
Ferrone, S
中科院分区：
文献类型：
--
作者：
Campoli, M;Chang, CC;Ferrone, S
在迄今为止进行的大多数基于T细胞的免疫疗法临床试验中观察到临床应答率较差。一个原因可能是存在异常的HLA I类抗原呈递在恶性病变。在用基于T细胞的免疫疗法治疗的患者的恶性病变中以及在基于T细胞的免疫疗法后经历临床应答的患者中复发的病变中已经观察到HLA I类异常的频率增加。这些观察结果与患者肿瘤的生长反映了肿瘤细胞的免疫选择的可能性是一致的，所述肿瘤细胞已经获得了逃避免疫识别的机制。(C)2002爱思唯尔科技有限公司版权所有。
Poor clinical response rates have been observed in the majority of the T cell-based immunotherapy clinical trials conducted to date. One reason might be the presence of abnormalities in HLA class I antigen presentation in malignant lesions. An increased frequency of HLA class I abnormalities has been observed in malignant lesions from patients treated with T cell-based immunotherapy and in lesions which have recurred in patients who had experienced clinical responses following T cell-based immunotherapy. These observations are compatible with the possibility that the outgrowth of a patient's tumor reflects immune selection of tumor cells which have acquired escape mechanisms from immune recognition. (C) 2002 Elsevier Science Ltd. All rights reserved.